Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.

Discovery medicine - 1 Sept 2012

Berg Marianne, Soreide Kjetil

Abstract excerpt

The promise of individualized treatment is gradually being fulfilled, and targeted therapy is becoming a powerful strategy to treat selected patients based on their molecular profile. For metastatic colorectal cancer (mCRC) patients anti-EGFR (epidermal growth factor receptor) targeted therapy has markedly improved disease control and survival. However, only a subgroup of patients with mCRC respond to anti-EGFR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Survival
Share to ErbB Receptors
Share to Genes, ras

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-akt

Share to ras Proteins

Source

Identifiers

PMID: 23021375

Genes

EGFR
KRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.PMID 23021375Read ↗

Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer.Semantic proximity Read ↗

Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions.Semantic proximity Read ↗

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.Semantic proximity Read ↗

Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.Semantic proximity Read ↗

Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.Semantic proximity Read ↗

An empirical review on the resistance mechanisms of epidermal growth factor receptor inhibitors and predictive molecular biomarkers in colorectal cancer.Semantic proximity Read ↗

The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies.Semantic proximity Read ↗

RAS and BRAF genes as biomarkers and target for personalised colorectal cancer therapy: An update.Semantic proximity Read ↗

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?Semantic proximity Read ↗

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.